We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





NGeneBio Showcases NGS-Based Oncology/Genetic Diseases Kits and NGenePlex nCoV qRT-PCR Kit Against COVID-19

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Image: NGenePlex nCoV qRT-PCR Kit (Photo courtesy of NGeneBio)
Image: NGenePlex nCoV qRT-PCR Kit (Photo courtesy of NGeneBio)

NGeneBio (Seoul, Korea) showcased its next-generation sequencing (NGS)-based oncology/genetic diseases kits and NGenePlex nCoV qRT-PCR kit against COVID-19 at AACC 2021.

Dedicated to achieving better health through laboratory medicine, the American Association for Clinical Chemistry, AACC, brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science.

At AACC 2021, NGeneBio showcased its NGS-based oncology/genetic diseases kits (BRCA/HEME/SOLID/ONCO/HLA). NGeneBio’s BRCAaccuTest and BRCAaccuTest PLUS are a reagent kit for producing libraries for analyzing the BRCA1 and BRCA2 genes using the NGS method, which analyzes genomic DNA derived from blood or FFPE tissue. The kit is intended for breast and ovarian cancer patients, HBOC (Hereditary breast and ovarian cancer syndrome) patients, and for family history or the age of breast cancer incidence.

Also on display at the event were NGeneBio’s HEMEaccuTest for molecular genetic test of multiple genes related hematologic malignancy; SOLIDaccuTest to explorer variants associated with solid tumors using a comprehensive method of NGS; HLAaccuTest All which is an in vitro diagnostic medical device for HLA (human leukocyte antigen) typing that can identify high-resolution histocompatibility antigens using NGS; and ONCOaccuPanel, a comprehensive solid tumor oncology NGS test.

In addition, NGeneBio demonstrated its NGeneAnalySys software for analysis of the genetic testing data produced by NGS and helps to report in clinical-grade for oncology test, alongside the EasyHLAanalyzer which provides the HLA typing identifying human leukocyte antigen for histocompatibility antigens using data from NGS. Also on display at AACC 2021 was NGeneBio’s NGenePlex nCoV qRT-PCR Kit which is a reagent of real-time reverse transcription-polymerase chain reaction (RT-PCR) assay intended for the qualitatively detecting nucleic acid of SARS-CoV-2 from patients infected or suspected of COVID-19.

Related Links:
NGeneBio 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article
ADLM
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.